

# Lynette M Sholl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6956730/publications.pdf>

Version: 2024-02-01

232  
papers

17,641  
citations

16437

64  
h-index

15716

125  
g-index

234  
all docs

234  
docs citations

234  
times ranked

21497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pseudoendocrine Sarcoma. American Journal of Surgical Pathology, 2022, 46, 33-43.	2.1	16
2	Atypical uterine polyps show morphologic and molecular overlap with mullerian adenosarcoma but follow a benign clinical course. Modern Pathology, 2022, 35, 106-116.	2.9	4
3	Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Modern Pathology, 2022, 35, 66-74.	2.9	33
4	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	0.5	151
5	Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood, 2022, 139, 357-368.	0.6	106
6	Neurotrophin Receptor Kinase. Journal of Molecular Diagnostics, 2022, 24, 107-108.	1.2	2
7	Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts. Modern Pathology, 2022, 35, 697-704.	2.9	9
8	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precision Oncology, 2022, 6, e2100448.	1.5	5
9	Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR. PLoS ONE, 2022, 17, e0264201.	1.1	4
10	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792.	0.5	50
11	Mast cells in lung damage of COVID-19 autopsies: A descriptive study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2237-2239.	2.7	13
12	Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Medicine, 2022, 14, 39.	3.6	22
13	Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Modern Pathology, 2022, 35, 1383-1397.	2.9	17
14	Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.. Journal of Clinical Oncology, 2022, 40, 9014-9014.	0.8	6
15	LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.. Journal of Clinical Oncology, 2022, 40, TPS8596-TPS8596.	0.8	7
16	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	3.4	117
17	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9066-9066.	0.8	1
18	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. Journal of Clinical Oncology, 2022, 40, 9065-9065.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021, 15, 27-42.	2.1	15
20	Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. <i>Modern Pathology</i> , 2021, 34, 613-626.	2.9	11
21	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 34-42.	3.2	87
22	Clinicopathological and molecular characteristics of prostate cancer diagnosed in young men aged up to 45 years. <i>Histopathology</i> , 2021, 78, 857-870.	1.6	1
23	Expanding the utility of cytology preparations in cancer biomarker testing. <i>Cancer Cytopathology</i> , 2021, 129, 337-340.	1.4	2
24	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	12.5	99
25	Intestinal metaplasia of the urinary tract harbors potentially oncogenic genetic variants. <i>Modern Pathology</i> , 2021, 34, 457-468.	2.9	9
26	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
27	BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100127.	0.6	2
28	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635.	1.3	5
29	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	3.2	25
30	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969.	7.7	87
31	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	1.0	51
32	Predictive "biomarker piggybacking"™: an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry. <i>Histopathology</i> , 2021, 79, 260-264.	1.6	7
33	Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with <i>MTAP</i> and <i>CDKN2A</i> copy number in malignant pleural mesothelioma. <i>Histopathology</i> , 2021, 78, 1032-1042.	1.6	20
34	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100146.	0.6	0
35	Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes. <i>Modern Pathology</i> , 2021, 34, 1763-1779.	2.9	8
36	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade. <i>Journal of Clinical Oncology</i> , 2021, 39, 9113-9113.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. Journal of Clinical Oncology, 2021, 39, 9121-9121.	0.8	2
38	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. Journal of Clinical Oncology, 2021, 39, 9119-9119.	0.8	0
39	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9018-9018.	0.8	4
40	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precision Oncology, 2021, 5, 726-732.	1.5	10
41	Changes in PD-L1 tumor proportion score are associated with <i>CD274</i> gene (encoding PD-L1) copy number variation in non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9029-9029.	0.8	0
42	Diffuse Tracheobronchial Neurofibromatosis and Papillomatosis. Key Diagnostic Aspects and Treatment. Annals of Thoracic Surgery, 2021, , .	0.7	0
43	Acquired Resistance to KRAS <sup>G12C</sup> Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	13.9	482
44	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. Modern Pathology, 2021, 34, 1935-1946.	2.9	15
45	Ectopic Anterior Mediastinal Pancreas: An Unusual Case of New Onset Hemoptysis. Annals of Thoracic Surgery, 2021, , .	0.7	0
46	SMARCA4 and Other SWItch/Sucose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of Thoracic Oncology, 2021, 16, 1176-1187.	0.5	49
47	Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer. , 2021, , .		8
48	Abstract 26: Association of aneuploidy score with clinical outcomes to immunotherapy in NSCLC. , 2021, , .		0
49	Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer, 2021, 157, 17-20.	0.9	3
50	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i> -mutant lung cancer. Science Translational Medicine, 2021, 13, eabb3738.	5.8	10
51	A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1433-1451.	2.5	11
52	In Response to "Reexamining the molecular findings in specialized stromal tumors of the prostate". Modern Pathology, 2021, 34, 2082-2083.	2.9	0
53	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
54	Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i> -mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903). Clinical Cancer Research, 2021, 27, 1604-1611.	3.2	18

#	ARTICLE	IF	CITATIONS
55	312â€¦Three-year outcomes with first-line pembrolizumab for metastatic nonâ€¦small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) â‰¥ 90%. , 2021, 9, A336-A336.		3
56	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. <i>Laboratory Investigation</i> , 2020, 100, 4-15.	1.7	52
57	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	0.5	203
58	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020, 140, 35-41.	0.9	22
59	Programmed death ligand 1 immunohistochemistry: can we agree on this?. <i>Histopathology</i> , 2020, 76, 189-190.	1.6	3
60	Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. <i>Modern Pathology</i> , 2020, 33, 560-565.	2.9	46
61	Biallelic PTCH1 Inactivation Is a Dominant Genomic Change in Sporadic Keratocystic Odontogenic Tumors. <i>American Journal of Surgical Pathology</i> , 2020, 44, 553-560.	2.1	20
62	Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1541-1548.	2.1	26
63	Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. <i>JCO Precision Oncology</i> , 2020, 4, 1084-1097.	1.5	11
64	Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 669-677.	0.6	5
65	Superior Vena Cava Syndrome associated with recurrent uterine adenosarcoma. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100613.	0.3	3
66	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. <i>Nature Communications</i> , 2020, 11, 6319.	5.8	203
67	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€¦Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	3.2	95
68	Identification of a RAS-activating <i>TMEM87Aâ€¦RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Nonâ€¦Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4072-4079.	3.2	13
69	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
70	ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis. <i>Modern Pathology</i> , 2020, 33, 2256-2268.	2.9	25
71	Poly (ADP Ribose) Polymerase Inhibitors for Cancer. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1126-1128.	1.2	0
72	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.	0.8	3

#	ARTICLE	IF	CITATIONS
73	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. <i>Modern Pathology</i> , 2020, 33, 2104-2114.	2.9	257
74	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	3.2	41
75	Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. <i>Cancer Research</i> , 2020, 80, 3197-3199.	0.4	7
76	Malignant tumours of the uterus and ovaries with Mullerian and germ cell or trophoblastic components have a somatic origin and are characterised by genomic instability. <i>Histopathology</i> , 2020, 77, 788-797.	1.6	20
77	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	0.5	234
78	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1477-1489.	1.2	14
79	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. <i>Annals of the American Thoracic Society</i> , 2020, 17, 550-554.	1.5	17
80	Biobanking and cryopreservation of human lung explants for omic analysis. <i>European Respiratory Journal</i> , 2020, 55, 1801635.	3.1	15
81	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. <i>JCO Precision Oncology</i> , 2020, 4, 307-318.	1.5	10
82	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	0.6	10
83	Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9577-9577.	0.8	2
84	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15113-e15113.	0.8	7
85	IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation. <i>ELife</i> , 2020, 9, .	2.8	13
86	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
87	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. <i>American Journal of Clinical Pathology</i> , 2019, 152, 97-108.	0.4	36
88	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	0.9	85
89	Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. <i>Lung Cancer</i> , 2019, 134, 96-99.	0.9	67
90	Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. <i>Histopathology</i> , 2019, 75, 546-551.	1.6	35

#	ARTICLE	IF	CITATIONS
91	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019, 127, 285-296.	1.4	39
92	Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 43-50.	0.6	8
93	Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1246-1251.	1.1	18
94	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
95	Characteristics of mismatch repair deficiency in sarcomas. <i>Modern Pathology</i> , 2019, 32, 977-987.	2.9	49
96	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	58
97	Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 659-666.	1.4	20
98	Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. <i>Modern Pathology</i> , 2019, 32, 830-843.	2.9	68
99	Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. <i>Human Pathology</i> , 2019, 86, 93-101.	1.1	19
100	Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 34-45.	7.7	310
101	Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9057-9057.	0.8	14
102	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9077-9077.	0.8	2
103	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9082-9082.	0.8	4
104	Changes in tumor mutational burden in serially biopsied non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14286-e14286.	0.8	1
105	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 814-821.	1.9	30
106	Meningioma transcription factors link cell lineage with systemic metabolic cues. <i>Neuro-Oncology</i> , 2018, 20, 1331-1343.	0.6	9
107	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. <i>Cancer Immunology Research</i> , 2018, 6, 630-635.	1.6	59
108	Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 401.	1.9	13

#	ARTICLE	IF	CITATIONS
109	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e131-e133.	0.5	30
110	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	0.5	408
111	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <i>Cancer Cytopathology</i> , 2018, 126, 253-263.	1.4	70
112	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346.	1.2	586
113	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159.	1.2	241
114	Interactive or static reports to guide clinical interpretation of cancer genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 458-464.	2.2	14
115	Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 955-958.	2.5	78
116	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations: The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	3.2	154
117	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
118	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386.	2.4	15
119	Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1433-1435.	0.5	2
120	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
121	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. <i>Modern Pathology</i> , 2018, 31, 1882-1890.	2.9	49
122	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	0.5	515
123	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR-T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018, 4, 1527.	3.4	522
124	Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5963-5976.	3.2	63
125	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
126	Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. <i>Lung Cancer</i> , 2018, 122, 72-75.	0.9	46



#	ARTICLE	IF	CITATIONS
127	Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9069-9069.	0.8	7
128	Translocations as Predictive Biomarkers in Lung Cancer. <i>Molecular Pathology Library</i> , 2018, , 159-171.	0.1	0
129	Development of HOPE-Genomics: An IT platform for patient-directed cancer genome sequencing education and return of results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1532-1532.	0.8	0
130	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3036-3036.	0.8	1
131	Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 204-213.	3.2	73
132	Detection of activating <i>MAP2K1</i> mutations in atypical hairy cell leukemia and hairy cell leukemia variant. <i>Leukemia and Lymphoma</i> , 2017, 58, 233-236.	0.6	39
133	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. <i>Oncolmunology</i> , 2017, 6, e1277308.	2.1	84
134	Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms. <i>Current Protocols in Human Genetics</i> , 2017, 92, 10.4.1-10.4.49.	3.5	5
135	A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1464-1476.	2.5	67
136	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , 2017, 19, 787-795.	1.1	46
137	Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour. <i>Histopathology</i> , 2017, 70, 1138-1146.	1.6	38
138	Quantitative computed tomography assessment of bronchiolitis obliterans syndrome after lung transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12943.	0.8	10
139	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 751-758.	1.2	350
140	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. <i>Nature Communications</i> , 2017, 8, 14922.	5.8	80
141	Molecular Analysis of Genetic Markers for Non-Hodgkin Lymphomas. <i>Current Protocols in Human Genetics</i> , 2017, 93, 10.14.1-10.14.29.	3.5	1
142	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , 2017, 14, 37-50.	0.8	15
143	Radiation-associated neoplasia: clinical, pathological and genomic correlates. <i>Histopathology</i> , 2017, 70, 70-80.	1.6	65
144	Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1464-1466.	0.5	6

#	ARTICLE	IF	CITATIONS
145	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	1.4	56
146	Next-generation sequencing of cytologic preparations: An analysis of quality metrics. <i>Cancer Cytopathology</i> , 2017, 125, 786-794.	1.4	51
147	GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 1720-1727.	2.9	33
148	Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1767-1772.	2.0	23
149	Successful Management of a Patient with Malignant Thyroid Teratoma. <i>Thyroid</i> , 2017, 27, 125-128.	2.4	21
150	Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. <i>JAMA Oncology</i> , 2017, 3, 740.	3.4	61
151	Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2017, 125, 615-626.	1.4	58
152	Medical Oncologists'™ Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. <i>Journal of Oncology Practice</i> , 2017, 13, e185-e196.	2.5	17
153	Molecular diagnostics of lung cancer in the clinic. <i>Translational Lung Cancer Research</i> , 2017, 6, 560-569.	1.3	43
154	Impact of MET inhibitors on survival among patients (pts) with <i>MET</i> exon 14 mutant ( <i>MET</i> <del>14</del> ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8511-8511.	0.8	26
155	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 92265-92274.	0.8	17
156	General medical oncologists assessment and use of targeted treatment for patients (pts) with metastatic nonsquamous non-small cell lung cancer (nsqNSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e18186-e18186.	0.8	0
157	Optimizing somatic genomic reporting and physician interpretation with web-based, interactive technologies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1517-1517.	0.8	0
158	Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1513-1513.	0.8	0
159	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	2.3	340
160	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1267-1272.	1.2	95
161	Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. <i>Modern Pathology</i> , 2016, 29, 893-903.	2.9	33
162	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016, 98, 1051-1066.	2.6	137

#	ARTICLE	IF	CITATIONS
163	Acquired <i>MET</i> D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1334-1341.	7.7	133
164	Preface. <i>Surgical Pathology Clinics</i> , 2016, 9, ix-x.	0.7	0
165	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016, 8, 79.	3.6	151
166	The Molecular Pathology of Lung Cancer. <i>Surgical Pathology Clinics</i> , 2016, 9, 353-378.	0.7	23
167	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	3.2	393
168	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	1.6	62
169	Inflammatory myofibroblastic tumour-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma. <i>Histopathology</i> , 2016, 69, 510-515.	1.6	2
170	Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF- $\kappa$ B regulatory genes. <i>Modern Pathology</i> , 2016, 29, 67-74.	2.9	71
171	Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. <i>Genetics in Medicine</i> , 2016, 18, 1011-1019.	1.1	108
172	Clinical and Molecular Characteristics of <i>NF1</i> -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3148-3156.	3.2	71
173	KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016, 11, 496-503.	0.5	65
174	<i>MET</i> Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016, 34, 721-730.	0.8	549
175	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. <i>JCI Insight</i> , 2016, 1, e89014.	2.3	110
176	Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. <i>Journal of Clinical Oncology</i> , 2016, 34, 11510-11510.	0.8	20
177	Deliberations of a precision medicine tumor board. <i>Journal of Clinical Oncology</i> , 2016, 34, e13005-e13005.	0.8	1
178	Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. <i>Journal of Clinical Oncology</i> , 2016, 34, 1500-1500.	0.8	2
179	Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. <i>Journal of Clinical Oncology</i> , 2016, 34, 11565-11565.	0.8	0
180	Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC). <i>Journal of Clinical Oncology</i> , 2016, 34, 9577-9577.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1648-1652.	0.5	52
182	Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 951-959.	0.5	100
183	Targeted genomic analysis of MÄllerian adenosarcoma. <i>Journal of Pathology</i> , 2015, 235, 37-49.	2.1	84
184	Myc protein expression correlates with MYC amplification in smallâ€cell lung carcinoma. <i>Histopathology</i> , 2015, 67, 81-89.	1.6	17
185	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.4	30
186	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	1.6	60
187	Commentary. <i>Clinical Chemistry</i> , 2015, 61, 587-588.	1.5	0
188	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2015, 10, 768-777.	0.5	357
189	Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. <i>Modern Pathology</i> , 2015, 28, 732-739.	2.9	85
190	Association of Polymerase â€“Mutated and Microsatellite-Unstable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. <i>JAMA Oncology</i> , 2015, 1, 1319.	3.4	523
191	Biomarkers in Lung Adenocarcinoma: A Decade of Progress. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 469-480.	1.2	66
192	Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 325-333.	1.0	9
193	BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. <i>Nucleic Acids Research</i> , 2015, 43, e19-e19.	6.5	161
194	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	3.2	96
195	Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. <i>Modern Pathology</i> , 2015, 28, 80-94.	2.9	190
196	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	1.8	49
197	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. <i>Modern Pathology</i> , 2015, 28, 1504-1514.	2.9	111
198	Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. <i>Journal of Clinical Oncology</i> , 2015, 33, 5511-5511.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8096-8096.	0.8	2
200	Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 626-635.	1.2	39
201	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. <i>Cancer Research</i> , 2014, 74, 4676-4684.	0.4	31
202	Thymic Measurements in Pathologically Proven Normal Thymus and Thymic Hyperplasia. <i>Academic Radiology</i> , 2014, 21, 733-742.	1.3	14
203	Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. <i>Cancer Genetics</i> , 2014, 207, 335-339.	0.2	16
204	Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. <i>Lung Cancer</i> , 2014, 86, 241-246.	0.9	82
205	The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy. <i>Cell</i> , 2014, 158, 564-578.	13.5	298
206	Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10299-10304.	3.3	77
207	Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 660-672.	1.2	70
208	Cancer patients'™ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1535-1535.	0.8	1
209	Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8032-8032.	0.8	5
210	Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8090-8090.	0.8	1
211	Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11030-11030.	0.8	0
212	Diagnosis of Primary and Metastatic Germ Cell Tumors Using Embryonic Stem Cell Transcription Factors. , 2013, , 177-186.		0
213	Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4532-4540.	3.2	307
214	ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1441-1449.	2.1	168
215	Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1434-1437.	0.5	51
216	Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2013, 8, 322-328.	0.5	145

#	ARTICLE	IF	CITATIONS
217	An analysis of the prevalence of <i>HER2</i> and <i>KRAS</i> mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8039-8039.	0.8	0
218	ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22042-e22042.	0.8	0
219	Medical management of pulmonary carcinoid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18512-e18512.	0.8	0
220	Pulmonary Clinicopathological Correlation In Long Term Survivors Following Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. <i>Blood</i> , 2013, 122, 2070-2070.	0.6	1
221	Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 5773-5779.	3.2	323
222	Emerging Evidence for MicroRNAs as Regulators of Cancer Stem Cells. <i>Cancers</i> , 2011, 3, 3957-3971.	1.7	9
223	Sox2 Expression in Pulmonary Non-small Cell and Neuroendocrine Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 55-61.	0.6	91
224	Sox2 Protein Expression is an Independent Poor Prognostic Indicator in Stage I Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1193-1198.	2.1	140
225	<i>EGFR</i> Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2010, 133, 922-934.	0.4	110
226	Molecular Analysis of Genetic Markers for Non-Hodgkin Lymphomas. <i>Current Protocols in Human Genetics</i> , 2010, 65, Unit 10.14.1-25.	3.5	1
227	Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloproliferative Neoplasms. <i>Current Protocols in Human Genetics</i> , 2010, 67, Unit 10.4.	3.5	0
228	Lung Adenocarcinoma with <i>EGFR</i> Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers. <i>Cancer Research</i> , 2009, 69, 8341-8348.	0.4	114
229	Immunohistochemical Analysis of Langerin in Langerhans Cell Histiocytosis and Pulmonary Inflammatory and Infectious Diseases. <i>American Journal of Surgical Pathology</i> , 2007, 31, 947-952.	2.1	77
230	Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. <i>Modern Pathology</i> , 2007, 20, 1028-1035.	2.9	51
231	JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. <i>Blood</i> , 2007, 110, 1634-1634.	0.6	0
232	Molecular assessment of paratesticular rhabdomyomas demonstrates recurrent findings, including a novel H3C2 p.K37I mutation. <i>Modern Pathology</i> , 0, , .	2.9	0